ShSPI Inhibits Thrombosis Formation and Ischemic Stroke In Vivo DOI Open Access
Ning Luan,

Han Cao,

Yunfei Wang

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(16), P. 9003 - 9003

Published: Aug. 19, 2024

Thrombotic diseases, emerging as a global public health hazard with high mortality and disability rates, pose significant threat to human longevity. Although current antithrombotic therapies are effective in treating these conditions, they often carry substantial risk of bleeding, highlighting the urgent need for safer therapeutic alternatives. Recent evidence has increasingly pointed connection between elastase activity thrombosis. In study, we investigated effects ShSPI, an inhibitor peptide derived from venom

Language: Английский

HELicobacter Pylori screening to prevent gastrointestinal bleeding in patients with acute Myocardial Infarction(HELP-MI SWEDEHEART) Design and rationale of a cluster randomized, crossover, registry-based clinical trial DOI Creative Commons
Robin Hofmann, Stefan James, Martin Sundqvist

et al.

American Heart Journal, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

The role of Helicobacter pylori (H. pylori) screening and eradication on reducing upper gastrointestinal bleeding (UGIB) complications after acute myocardial infarction (MI) is uncertain. HELicobacter Pylori to prevent in patients with MI (HELP-MI SWEDEHEART) trial aims determine whether systematic H. compared usual care reduces UGIB, mortality, cardiovascular outcomes MI. A cluster randomized, crossover, registry-based clinical using SWEDEHEART as platform for study population definition source data collection combination nationwide Swedish health registries. Thirty-five hospitals, organized into 18 clusters based percutaneous coronary intervention networks, were randomized either routine adults type-1 or care. After one year, a 2-month blanking period was followed by crossover the alternate allocation year. enrolment concluded additional year follow-up. primary endpoint UGIB. Secondary endpoints include all-cause death, readmission MI, stroke, heart failure. Endpoints will be reported combined (Net Adverse Clinical Events; Major Cardiac Cerebrovascular Events) separately. analysis all available follow-up time corresponding maximum 3 years 2 months. HELP-MI utility reduce UGIB improve By integrating national registry pragmatic design, it has potential provide evidence effect implementation part ClinicalTrials.gov, NCT05024864.

Language: Английский

Citations

0
Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease DOI
Jonatan Wärme, Martin Sundqvist, Stefan James

et al.

Nature Reviews Cardiology, Journal Year: 2024, Volume and Issue: 21(8), P. 593 - 593

Published: May 2, 2024

Language: Английский

Citations

3
Reply to ‘Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease’ DOI
Azita H. Talasaz, Behnood Bikdeli

Nature Reviews Cardiology, Journal Year: 2024, Volume and Issue: 21(8), P. 594 - 595

Published: May 2, 2024

Language: Английский

Citations

2
Switching from cangrelor to oral P2Y 12 inhibitors: a focused review on drug-drug interactions DOI
G. Occhipinti,

Luis Ortega-Paz,

Francesco Franchi

et al.

Expert Opinion on Drug Metabolism & Toxicology, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 12

Published: Oct. 16, 2024

Introduction . Cangrelor, the only intravenous platelet P2Y12 receptor inhibitor, is characterized by a prompt and potent inhibition, with rapid offset of action. Large-scale clinical trials have shown that cangrelor reduce peri-procedural thrombotic events among patients undergoing percutaneous coronary interventions not pre-treated an oral inhibitor. However, high occupancy provided raises concerns for drug-drug interactions (DDIs) when transitioning to inhibitors.

Language: Английский

Citations

2
Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low‐Dose Rivaroxaban or the Combination: Secondary Analysis of the COMPASS Randomised Controlled Trial DOI
Yu‐Xiao Yang, Yaling Li, Jun Li

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 5, 2024

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Language: Английский

Citations

1
ShSPI Inhibits Thrombosis Formation and Ischemic Stroke In Vivo DOI Open Access
Ning Luan,

Han Cao,

Yunfei Wang

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(16), P. 9003 - 9003

Published: Aug. 19, 2024

Thrombotic diseases, emerging as a global public health hazard with high mortality and disability rates, pose significant threat to human longevity. Although current antithrombotic therapies are effective in treating these conditions, they often carry substantial risk of bleeding, highlighting the urgent need for safer therapeutic alternatives. Recent evidence has increasingly pointed connection between elastase activity thrombosis. In study, we investigated effects ShSPI, an inhibitor peptide derived from venom

Language: Английский

Citations

0